(Q82526829)

English

Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma

scientific article published on 01 December 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Andrzej Hellmann

1

object named as

Andrzej Hellmann

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Simon Rule

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Ofer Shpilberg

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Huaibao Feng

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Helgi van de Velde

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Hamina Patel

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Donna M Skee

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Suzette Girgis

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

1 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

50

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

781-791

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087865%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug interaction studies: study design, data analysis, and implications for dosing and labeling

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib in combination with dexamethasone for relapsed multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of adverse drug reactions in geriatric inpatients using a computerised drug database

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinically relevant drug-drug interactions in oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifampin drastically reduces plasma concentrations and effects of oral midazolam.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New developments in the treatment of patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proteasome inhibition measurements: clinical application

1 reference

https://pubmed.ncbi.nlm.nih.gov/22087865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q82526829&oldid=2221258811"